Prevalence of discordant GH and IGF-I levels in acromegalics at diagnosis, after surgical treatment and during treatment with octreotide LAR®

Growth Hormone and IGF Research

Volumn 18, Issue 5, 2008, Pages 389-393

  Machado, Evelyn Oliveira ^a   Taboada, Giselle F ^a   Neto, Leonardo Vieira ^a   Haute, Flávia R van ^a   Corrêa, Lívia L ^a   Balarini, Giovanna A ^a,b   Shrank, Yolanda ^c   Goulart, Marcio ^c   Gadelha, Mônica R ^a,b  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b Instituto Estadual de Diabetes e Endocrinologia Luiz Capriglione   (Brazil)

^c Medicina diagnóstica ^*  (Brazil)

Author keywords

Acromegaly; Discordance; Growth hormone; Insulin like growth factor type I

Indexed keywords

GROWTH HORMONE; OCTREOTIDE; OCTREOTIDE LAR; SOMATOMEDIN C;

ACROMEGALY; ADULT; AGED; ARTICLE; CONTROLLED STUDY; ENDOCRINE SURGERY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; ORAL GLUCOSE TOLERANCE TEST; PREVALENCE; PRIORITY JOURNAL; REFERENCE VALUE; RETROSPECTIVE STUDY; TREATMENT DURATION;

ACROMEGALY; AGED; AGED, 80 AND OVER; FEMALE; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; OCTREOTIDE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 46949108045     PISSN: 10966374     EISSN: 15322238     Source Type: Journal    
DOI: 10.1016/j.ghir.2008.02.001     Document Type: Article

References (24)

1. Giustina A., Barkan A., Casanueva F., et al. Criteria for cure of acromegaly: a consensus statement. J. Clin. Endocrinol. Metab. 85 (2000) 526-529
2. The Growth Hormone Research Society and The Pituitary Society, Biochemical assessment and long-term monitoring in patients with acromegaly: statement from a joint consensus conference, J. Clin. Endocrinol. Metab. 89 (2004) 3099-3102.
3. Taboada G.F., Correa L.L., Machado E.O., et al. Two hour mean GH is not superior to basal GH for the follow-up of acromegalic patients treated with Octreotide LAR. GH and IGF Res. 17 (2007) 77-81
4. Holdaway I.M., Rajasoorya R.C., and Gamble G.D. Factors influencing mortality in acromegaly. J. Clin. Endocrinol. Metab. 89 (2004) 667-674
5. Ayuk J., Clayton R.N., Holder G., et al. Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly. J. Clin. Endocrinol. Metab. 89 (2004) 1613-1617
6. Dimaraki E.V., Jaffe C.A., Demott-Friberg R., et al. Acromegaly with apparently normal GH secretion: implications for diagnosis and follow-up. J. Clin. Endocrinol. Metab. 87 (2002) 3537-3542
7. Costa A.C.F., Rossi A., Martinelli C.E., et al. Assessment of disease activity in treated acromegalic patients using a sensitive GH assay: should we achieve strict normal GH levels for a biochemical cure?. J. Clin. Endocrinol. Metab. 87 (2002) 3142-3147
8. Cozzi R., Attanasio R., Grottoli S., et al. Treatment of acromegaly with SS analogues: should GH and IGF-I target levels be lowered to assert a tight control lo the disease?. J. Endocrinol. Invest. 27 (2004) 1040-1047
9. Kauppinen-Makelin R., Sane T., Reumanen A., et al. A nationwide survey of mortality in acromegaly. J. Clin. Endocrinol. Metab. 90 (2005) 4081-4086
10. Orme S.M., McNally R.J., Cartwright R.A., et al. Mortality and cancer incidence in acromegaly a retrospective cohort study. United Kingdom Acromegaly study group. J. Clin. Endocrinol. Metab. 83 (1998) 2730-2734
11. Rajasoorya C., Holdaway I.M., Wrightson P., et al. Determinants of clinical outcome and survival in acromegaly. Clin. Endocrinol. 41 (1994) 95-102
12. Swearingen B., Barker F.G., Katznelson L., et al. Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J. Clin. Endocrinol. Metab. 83 (1998) 3419-3426
13. Beauregard C., Truong U., and Hardy J. Long-term outcome and mortality after transsphenoidal surgery adenomectomy for acromegaly. Clin. Endocrinol. 58 (2003) 86-91
14. Pruder J.J., Nilavar S., and Port K.D. Relationship between disease related morbity and biochemical markers of activity in patients with acromegaly. J. Clin. Endocrinol. Metab. 90 (2005) 1972-1978
15. Brabant G. Insulin-like growth factor-I: marker for diagnosis of acromegaly and monitoring the efficacy of treatment. Eur. J. Endocrinol. 148 (2003) 15-20
16. Sheppard M.C. The critical parameters in GH excess. J. Endocrinol. Invest. 28 (2005) 92-95
17. Strasburger C.J. IGF-I and mortality in patients with acromegaly. J. Endocrinol. Invest. 28 (2005) 78-80
18. Barkan A.L., Halasz I., and Dornfeld K.J. Pituitary irradiation is ineffective in normalizing plasma insulin-like growth factor I in patients with acromegaly. J. Clin. Endocrinol. Metab. 32 (1997) 3187-3191
19. Jenkins P.J., Bates P., and Carson M.N. Conventional pituitary irradiation is effective in lowering serum growth hormone and insulin-like growth factor-I in patients with acromegaly. J. Clin. Endocrinol. Metab. 91 (2006) 1239-1245
20. Cozzi R., Attanasio R., Montini M., et al. Four-year treatment with octreotide-long-acting repeatable in 110 acromegalic patients: predictive value of short-term results?. J. Clin. Endocrinol. Metab. 88 (2003) 3090-3098
21. Boguszewski C.L. Molecular heterogeneity of human growth hormone from basic research to clinical applications. J. Endocrinol. Invest. 26 (2003) 274-288
22. Sheppard M.C. GH and mortality in acromegaly. J. Endocrinol. Invest. 28 (2005) 75-77
23. Von Werder K. Biochemical evidence supporting the Cortina criteria. J. Endocrinol. Invest. 28 (2005) 81-83
24. Gullu S., Keles H., and Delibasi T. Remission criteria for the follow-up of patients with acromegaly. Eur. J. Endocrinol. 150 (2004) 465-471